Serum 25-hydroxyvitamin D levels are not associated with adverse outcomes in Clostridium difficile infection

Dejan Micic, Krishna Rao, Bruno Caetano Trindade, Seth T. Walk, Elizabeth Chenoweth, Ruchika Jain, Itishree Trivedi, Kavitha Santhosh, Vincent B. Young, David M. Aronoff

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Clostridium difficile infection (CDI) is a significant source of healthcare-associated morbidity and mortality. This study investigated whether serum 25-hydroxyvitamin D is associated with adverse outcomes from CDI. Patients with CDI were prospectively enrolled. Charts were reviewed and serum 25-hydroxyvitamin D was measured. The primary outcome was a composite definition of severe disease: fever (temperature > 38°C), acute organ dysfunction, or serum white blood cell count > 15,000 cells/μL within 24-48 hours of diagnosis; lack of response to therapy by day 5; and intensive care unit admission; colectomy; or death within 30 days. Sixty-seven patients were included in the final analysis. Mean (±SD) serum 25- hydroxyvitamin D was 26.1 (±18.54) ng/mL. Severe disease, which occurred in 26 (39%) participants, was not associated with serum 25-hydroxyvitamin D [odds ratio (OR) 1.00; 95% confidence interval (CI) 0.96-1.04]. In the adjusted model for severe disease only serum albumin (OR 0.12; 95%CI 0.02-0.64) and diagnosis by detection of stool toxin (OR 5.87; 95%CI 1.09-31.7) remained independent predictors. We conclude that serum 25-hydroxyvitamin D is not associated with the development of severe disease in patients with CDI.

Original languageEnglish (US)
Pages (from-to)50-55
Number of pages6
JournalInfectious Disease Reports
Volume7
Issue number3
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Clostridium Infections
Clostridium difficile
Serum
Odds Ratio
Confidence Intervals
Colectomy
Leukocyte Count
Serum Albumin
Intensive Care Units
25-hydroxyvitamin D
Fever
Morbidity
Delivery of Health Care
Temperature
Mortality

Keywords

  • Biomarkers
  • Clostridium difficile
  • Colitis
  • Vitamin D

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Serum 25-hydroxyvitamin D levels are not associated with adverse outcomes in Clostridium difficile infection. / Micic, Dejan; Rao, Krishna; Trindade, Bruno Caetano; Walk, Seth T.; Chenoweth, Elizabeth; Jain, Ruchika; Trivedi, Itishree; Santhosh, Kavitha; Young, Vincent B.; Aronoff, David M.

In: Infectious Disease Reports, Vol. 7, No. 3, 01.01.2015, p. 50-55.

Research output: Contribution to journalArticle

Micic, D, Rao, K, Trindade, BC, Walk, ST, Chenoweth, E, Jain, R, Trivedi, I, Santhosh, K, Young, VB & Aronoff, DM 2015, 'Serum 25-hydroxyvitamin D levels are not associated with adverse outcomes in Clostridium difficile infection', Infectious Disease Reports, vol. 7, no. 3, pp. 50-55. https://doi.org/10.4081/idr.2015.5979
Micic, Dejan ; Rao, Krishna ; Trindade, Bruno Caetano ; Walk, Seth T. ; Chenoweth, Elizabeth ; Jain, Ruchika ; Trivedi, Itishree ; Santhosh, Kavitha ; Young, Vincent B. ; Aronoff, David M. / Serum 25-hydroxyvitamin D levels are not associated with adverse outcomes in Clostridium difficile infection. In: Infectious Disease Reports. 2015 ; Vol. 7, No. 3. pp. 50-55.
@article{5d8a10e585d94b3a9930da7e38dfe578,
title = "Serum 25-hydroxyvitamin D levels are not associated with adverse outcomes in Clostridium difficile infection",
abstract = "Clostridium difficile infection (CDI) is a significant source of healthcare-associated morbidity and mortality. This study investigated whether serum 25-hydroxyvitamin D is associated with adverse outcomes from CDI. Patients with CDI were prospectively enrolled. Charts were reviewed and serum 25-hydroxyvitamin D was measured. The primary outcome was a composite definition of severe disease: fever (temperature > 38°C), acute organ dysfunction, or serum white blood cell count > 15,000 cells/μL within 24-48 hours of diagnosis; lack of response to therapy by day 5; and intensive care unit admission; colectomy; or death within 30 days. Sixty-seven patients were included in the final analysis. Mean (±SD) serum 25- hydroxyvitamin D was 26.1 (±18.54) ng/mL. Severe disease, which occurred in 26 (39{\%}) participants, was not associated with serum 25-hydroxyvitamin D [odds ratio (OR) 1.00; 95{\%} confidence interval (CI) 0.96-1.04]. In the adjusted model for severe disease only serum albumin (OR 0.12; 95{\%}CI 0.02-0.64) and diagnosis by detection of stool toxin (OR 5.87; 95{\%}CI 1.09-31.7) remained independent predictors. We conclude that serum 25-hydroxyvitamin D is not associated with the development of severe disease in patients with CDI.",
keywords = "Biomarkers, Clostridium difficile, Colitis, Vitamin D",
author = "Dejan Micic and Krishna Rao and Trindade, {Bruno Caetano} and Walk, {Seth T.} and Elizabeth Chenoweth and Ruchika Jain and Itishree Trivedi and Kavitha Santhosh and Young, {Vincent B.} and Aronoff, {David M.}",
year = "2015",
month = "1",
day = "1",
doi = "10.4081/idr.2015.5979",
language = "English (US)",
volume = "7",
pages = "50--55",
journal = "Infectious Disease Reports",
issn = "2036-7430",
publisher = "PagePress",
number = "3",

}

TY - JOUR

T1 - Serum 25-hydroxyvitamin D levels are not associated with adverse outcomes in Clostridium difficile infection

AU - Micic, Dejan

AU - Rao, Krishna

AU - Trindade, Bruno Caetano

AU - Walk, Seth T.

AU - Chenoweth, Elizabeth

AU - Jain, Ruchika

AU - Trivedi, Itishree

AU - Santhosh, Kavitha

AU - Young, Vincent B.

AU - Aronoff, David M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Clostridium difficile infection (CDI) is a significant source of healthcare-associated morbidity and mortality. This study investigated whether serum 25-hydroxyvitamin D is associated with adverse outcomes from CDI. Patients with CDI were prospectively enrolled. Charts were reviewed and serum 25-hydroxyvitamin D was measured. The primary outcome was a composite definition of severe disease: fever (temperature > 38°C), acute organ dysfunction, or serum white blood cell count > 15,000 cells/μL within 24-48 hours of diagnosis; lack of response to therapy by day 5; and intensive care unit admission; colectomy; or death within 30 days. Sixty-seven patients were included in the final analysis. Mean (±SD) serum 25- hydroxyvitamin D was 26.1 (±18.54) ng/mL. Severe disease, which occurred in 26 (39%) participants, was not associated with serum 25-hydroxyvitamin D [odds ratio (OR) 1.00; 95% confidence interval (CI) 0.96-1.04]. In the adjusted model for severe disease only serum albumin (OR 0.12; 95%CI 0.02-0.64) and diagnosis by detection of stool toxin (OR 5.87; 95%CI 1.09-31.7) remained independent predictors. We conclude that serum 25-hydroxyvitamin D is not associated with the development of severe disease in patients with CDI.

AB - Clostridium difficile infection (CDI) is a significant source of healthcare-associated morbidity and mortality. This study investigated whether serum 25-hydroxyvitamin D is associated with adverse outcomes from CDI. Patients with CDI were prospectively enrolled. Charts were reviewed and serum 25-hydroxyvitamin D was measured. The primary outcome was a composite definition of severe disease: fever (temperature > 38°C), acute organ dysfunction, or serum white blood cell count > 15,000 cells/μL within 24-48 hours of diagnosis; lack of response to therapy by day 5; and intensive care unit admission; colectomy; or death within 30 days. Sixty-seven patients were included in the final analysis. Mean (±SD) serum 25- hydroxyvitamin D was 26.1 (±18.54) ng/mL. Severe disease, which occurred in 26 (39%) participants, was not associated with serum 25-hydroxyvitamin D [odds ratio (OR) 1.00; 95% confidence interval (CI) 0.96-1.04]. In the adjusted model for severe disease only serum albumin (OR 0.12; 95%CI 0.02-0.64) and diagnosis by detection of stool toxin (OR 5.87; 95%CI 1.09-31.7) remained independent predictors. We conclude that serum 25-hydroxyvitamin D is not associated with the development of severe disease in patients with CDI.

KW - Biomarkers

KW - Clostridium difficile

KW - Colitis

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84946023003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946023003&partnerID=8YFLogxK

U2 - 10.4081/idr.2015.5979

DO - 10.4081/idr.2015.5979

M3 - Article

AN - SCOPUS:84946023003

VL - 7

SP - 50

EP - 55

JO - Infectious Disease Reports

JF - Infectious Disease Reports

SN - 2036-7430

IS - 3

ER -